NCT05429788View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 18, 2022

Primary Completion Date

November 8, 2022

Study Completion Date

November 8, 2022

Conditions
Social Anxiety Disorder
Interventions
DRUG

Low dose RLS103

3 mg CBD inhaled powder administered before public speaking challenge

DRUG

High dose RLS103

6 mg CBD inhaled powder administered before public speaking challenge

DRUG

placebo inhaled dry powder

placebo inhaled powder administered before public speaking challenge

Trial Locations (3)

90024

Receptor 102, Los Angeles

90502

Receptor 103, Torrance

92056

Receptor 105, Oceanside

Sponsors
All Listed Sponsors
lead

Receptor Life Sciences

INDUSTRY